Exchange: NASDAQ·Updated 03:50 PM EDT
News
all
press releases
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks
More News
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of $26.34 billion.read more...
Benzinga
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Zacks
Insmed to Present at September 2026 Investor Conferences
Insmed to Present at September 2026 Investor Conferences Insmed to Present at September 2026 Investor Conferences PR Newswire BRIDGEWATER, N.J., Aug. 26, 2026 BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company...
PR Newswire
BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease BRINSUPRI (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients...
PR Newswire
Top Analyst Reports for Visa, Lam Research & Caterpillar
Visa's payments growth, Lam Research's AI-driven demand and Caterpillar's broad market momentum headline today's top analyst reports.
Zacks
Insmed (INSM) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of $28.82 billion.read more...
Benzinga
What Insmed Stock's Premium Is Actually Buying
What Insmed Stock's Premium Is Actually Buying...
Yahoo! Finance: News
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
Zacks

Advertisement|Remove ads.